Aktis Oncology targets a valuation of up to $945.4 million in its upsized IPO, with Eli Lilly as an anchor investor, highlighting strong investor interest in biotech. This partnership builds on their 2024 collaboration to develop tumor-targeting radiopharmaceuticals.

Researchers at NIH show that transferring healthy mitochondria from glial cells to nerve cells can potentially reduce nerve pain and degeneration associated with diabetic and chemotherapy-induced neuropathy. This breakthrough could lead to new therapeutic strategies for managing nerve-related pain.

Researchers have developed the first minimally invasive coronary artery bypass method, potentially providing a safer alternative for high-risk patients compared to traditional open-heart surgery. This breakthrough could significantly impact surgical approaches in cardiovascular care.

The National Organization for Rare Disorders (NORD) has extended its exclusive partnership with Medlive to enhance medical education aimed at improving outcomes for rare disease patients. This collaboration underscores the commitment to advancing knowledge and care in the rare disease community.

The Department of Health and Human Services has released an updated list of certified laboratories and Instrumented Initial Testing Facilities for urine and oral fluid drug testing, adhering to the Mandatory Guidelines for Federal Workplace Drug Testing Programs. This update is relevant for federal agencies involved in drug testing compliance.

FDA has determined the regulatory review period for ZURZUVAE, which is necessary for patent extension applications. This determination is part of the legal requirements for patent claims related to the drug.

Intellia is set to report Phase 3 trial results for a potential treatment for hereditary angioedema in the first half of 2026, amidst a backdrop of significant clinical trial activity in rare diseases. Despite recent challenges, including a study participant's death and program suspensions, the biotech sector is regaining momentum with key readouts expected across various conditions.

FDA has determined the regulatory review period for MEDIBEACON, which is necessary for a patent extension application. This decision is part of the regulatory process for medical devices and may impact future market exclusivity.

The FDA has determined the regulatory review period for BRENZAVVY, which is necessary for the patent extension application process. This determination is part of the legal requirements for patent claims related to the drug.

FDA has determined the regulatory review period for AUGTYRO, which is necessary for a patent extension application. This determination is part of the legal requirements for patent claims related to human drug products.

The Department of Health and Human Services proposes amendments to the Child Care and Development Fund regulations, aiming to reduce administrative costs for states. Key changes include rescinding the 7% family co-payment limit and altering payment structures for providers.

The Health Resources and Services Administration (HRSA) has proposed updates to the Women's Preventive Services Guidelines, specifically regarding cervical cancer screening. These updates are part of a cooperative agreement under the Women's Preventive Services Initiative (WPSI) and aim to enhance preventive care for women.

The FDA has determined the regulatory review period for IZERVAY, which is necessary for the patent extension process. This determination is part of the compliance with legal requirements for patent applications submitted to the USPTO.

The CDC has initiated updates to the childhood immunization schedule following a presidential memorandum. This action reflects ongoing efforts to enhance public health and vaccination strategies.

FDA revokes Emergency Use Authorizations for the Lucira by Pfizer COVID-19 & Flu Test and the Lucira by Pfizer COVID-19 & Flu Home Test at the request of Pfizer Inc. The decision reflects ongoing evaluations of diagnostic device efficacy and safety.

The FDA has determined that MYSOLINE (primidone) suspension, 250 mg/5 mL, was withdrawn from sale due to safety or effectiveness concerns. Consequently, the FDA will not accept or approve abbreviated new drug applications for this formulation.

A recent study highlights the successful treatment of posttransplant refractory pure red cell aplasia caused by parvovirus B19 infection. This research contributes to understanding treatment options for this rare condition.

The DEA and HHS have extended telemedicine flexibilities for prescribing controlled medications until December 31, 2026. This decision supports continued access to care for patients requiring controlled substances, reflecting ongoing adaptations in healthcare delivery.

The Office of Refugee Resettlement plans to award a $1 million cooperative agreement to the Welcoming Initiative for Newcomers in San Diego. This funding aims to assess state readiness for implementing a new refugee resettlement framework.

NIOSH has announced its decision to evaluate a petition for including employees from United Nuclear Corporation in Hematite, Missouri, in the Special Exposure Cohort. This could impact compensation eligibility under the Energy Employees Occupational Illness Compensation Program Act.